GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Hold” from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received a consensus recommendation of “Hold” from the fifteen research firms that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $3.8125.

GDRX has been the subject of several analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $3.50 target price on shares of GoodRx in a report on Friday, May 8th. Citigroup reiterated a “buy” rating on shares of GoodRx in a report on Thursday. Weiss Ratings lowered shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday. Finally, TD Cowen increased their price objective on shares of GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Monday, May 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GDRX. Lazard Asset Management LLC lifted its stake in shares of GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after acquiring an additional 5,201 shares during the last quarter. Brevan Howard Capital Management LP boosted its holdings in GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after acquiring an additional 6,842 shares during the period. Hirtle Callaghan & Co LLC grew its position in GoodRx by 60.3% in the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after acquiring an additional 6,869 shares during the last quarter. Tower Research Capital LLC TRC grew its position in GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after acquiring an additional 7,580 shares during the last quarter. Finally, Quarry LP purchased a new stake in GoodRx in the third quarter worth $33,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Up 3.1%

Shares of GDRX opened at $2.96 on Monday. The company has a market cap of $1.01 billion, a PE ratio of 49.34, a P/E/G ratio of 1.33 and a beta of 1.60. The business has a fifty day moving average of $2.83 and a 200 day moving average of $2.51. GoodRx has a 52-week low of $1.77 and a 52-week high of $5.81. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The company had revenue of $194.01 million during the quarter, compared to analyst estimates of $185.40 million. During the same period in the previous year, the firm earned $0.09 earnings per share. GoodRx’s quarterly revenue was down 4.4% compared to the same quarter last year. On average, sell-side analysts expect that GoodRx will post 0.17 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.